Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01071850 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 412
- Enrollment target
- 20
- Study locations
NCT01071850: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Astellas Pharma.
NCT01071850 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Astellas Pharma. The registered enrollment target is 412 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01071850, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 412 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate the efficacy, safety, and tolerability of multiple doses of ASP1941 compared to placebo over 12 weeks of therapy in adult patients with type 2 diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG ipragliflozin
Study Locations (20)
California
- Clinical Innovations, Inc. - Costa Mesa
- Del Rosario Medical Clinic, Inc - Huntington Park
- Torrance Clinical Research - Lomita
- San Diego Managed Care Group Clinical Research - San Diego
Florida
- PAB Clinical Research - Brandon
- Clinical Therapeutics Corp. - Coral Gables
- A.G.A Clinical Trials DBA Neostart Group - Hialeah
- Suncoast Clinical Research - New Port Richey
Alabama
- Parkway Medical Center - Birmingham
- Winston Technology Research, LLC - Haleyville
Arizona
- Desert Clinical Research - Mesa
- Central Phoenix Medical Clinic - Phoenix
Georgia
- CSRA Partners in Health, Inc. - Augusta
- Atlanta Vascular Research Foundation, Atlanta Cardiology & Primary Care P.C. - Tucker
Illinois
- Cedar Crosse Research Center - Chicago
- APEX Medical Research, AMR, Inc - Chicago
Arkansas
- Paul W. Davis, MD, PA - Pine Bluff
Colorado
- Expresscare Clinical Research - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2010-03-03 |
| Est. Completion | 2011-04-11 |
| Phase | Phase 2 |
What the finished NCT01071850 record still lists
NCT01071850 is an interventional study that assigns participants to a tested intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01071850 names 20 study sites across 10 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01071850 about?
NCT01071850 is a clinical study titled "A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus". Evaluate the efficacy, safety, and tolerability of multiple doses of ASP1941 compared to placebo over 12 weeks of therapy in adult patients with type 2 diabetes mellitus.
What is the current status of trial NCT01071850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 412 participants. The study started on 2010-03-03. Estimated completion is 2011-04-11.
What conditions does trial NCT01071850 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01071850?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), ipragliflozin (DRUG).
Who is sponsoring clinical trial NCT01071850?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01071850 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01071850's enrollment target sits among peer trials
412 91st of 348 higher than 258 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI